AI & Technical question
Abridge explicitly uses LLM judges, rule-based evaluators, human annotation, and online monitoring. How would you decide which of these methods belongs at each stage of the eval lifecycle, and what failure modes, cost/speed tradeoffs, and confidence limits would you communicate before teams rely on them for launch decisions?
- Abridge
- AI & Technical
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests understanding of where each evaluation method fits in a clinical AI eval lifecycle and the honesty to communicate their limits.
How to approach it
- Use rule based evaluators for fast, cheap, deterministic checks like required fields, format, or banned phrases, at every stage including CI.
- Use LLM judges for scalable quality scoring during rapid iteration, where human review would be too slow, but calibrate them against human labels first.
- Reserve human annotation for high stakes launch decisions and for building the ground truth set LLM judges are calibrated against.
- Use online monitoring in production to catch drift and rare failure modes that offline evals with static datasets cannot surface.
- Communicate LLM judge agreement rates with clinicians explicitly, so teams know when a passing eval score still needs a human check.
What a strong answer includes
- Explains that LLM judges can be miscalibrated or gamed, so their scores need periodic recalibration against fresh human labels.
- Notes cost and speed tradeoffs concretely: human annotation is the gold standard but too slow for daily iteration decisions.
- Insists that launch decisions in clinical settings should never rest on LLM judge scores alone without a human sampling check.
Common mistakes
- Treating an LLM judge score as equivalent to clinician judgment for a launch decision.
- Using human annotation for every iteration, which is too slow to support daily development.
Likely follow-up questions
- How often would you recalibrate the LLM judges against human labels?
- What would you do if the LLM judge and human reviewers disagree on a launch decision?
More ai & technical questions
- Abridge has a post-training approach that uses clinician edits, final notes, and EHR context to improve note generation. How would you define the hypotheses, stage gates, and success metrics to take it from offline research to shadow mode to a limited production launch? What evidence would be required at each step to continue, pause, or kill the effort?Abridge · AI & Technical · Hard
- For a model that turns patient-clinician conversations into structured clinical notes, what evaluation suite would you use beyond aggregate quality scores? Specify the failure modes you would prioritize, how you would segment risk by workflow or note type, and the thresholds or escalation paths you would require before declaring the model safe enough to scale.Abridge · AI & Technical · Hard
- Abridge has access to de-identified conversations, clinician edits, final signed notes, EHR context, and downstream care actions, but each signal differs in coverage, cost, bias, and clinical relevance. How would you prioritize which signals to use first for post-training, and what framework would you use to decide whether a sparse, subjective, or expensive signal is still worth operationalizing?Abridge · AI & Technical · Hard
- A chart-aware CDS assistant must feel fast enough for live clinical use while staying reliable and evidence-grounded. How would you work with engineering and ML to define the system tradeoffs and product requirements around latency, retrieval quality, grounding, fallback behavior, and failure handling, and what technical or model-level changes would you prioritize first if response time improved only by reducing answer quality?Abridge · AI & Technical · Hard
- Abridge has a new AI-assisted clinician workflow whose model quality is improving but still imperfect. What launch criteria would you set before exposing it in live care, how would you combine offline evals, human review, and UX guardrails, and how would you phase the rollout to manage clinical and compliance risk?Abridge · AI & Technical · Hard
- Production monitoring shows a model improves average note quality but increases rare critical errors. How would you investigate whether this is a measurement artifact, a distribution shift, or a real safety regression, and how would you decide between shipping, pausing, rolling back, or narrowing scope?Abridge · AI & Technical · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 1: Foundations: the model and the decisions it forces on you
- Chapter 8: Evals: define good and make the number defensible
- Chapter 6: Agents and agentic architecture